Delcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Increase in Short Interest

Delcath Systems, Inc. (NASDAQ:DCTHGet Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 928,700 shares, a growth of 13.1% from the April 15th total of 821,200 shares. Based on an average daily volume of 206,800 shares, the short-interest ratio is currently 4.5 days.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DCTH. upgraded Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. HC Wainwright lifted their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, March 27th. Finally, Stephens began coverage on shares of Delcath Systems in a research note on Tuesday. They issued an “overweight” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from, Delcath Systems presently has an average rating of “Moderate Buy” and a consensus price target of $19.80.

Check Out Our Latest Research Report on DCTH

Insiders Place Their Bets

In related news, Director Gil Aharon acquired 26,882 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was acquired at an average price of $3.72 per share, with a total value of $100,001.04. Following the completion of the transaction, the director now owns 1,069,710 shares of the company’s stock, valued at $3,979,321.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 17.94% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC increased its holdings in shares of Delcath Systems by 94.9% during the first quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock worth $7,950,000 after buying an additional 811,555 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock valued at $204,000 after purchasing an additional 9,000 shares in the last quarter. Armistice Capital LLC bought a new position in Delcath Systems in the 3rd quarter valued at $664,000. WealthPlan Investment Management LLC acquired a new position in Delcath Systems in the fourth quarter worth $73,000. Finally, Stonepine Capital Management LLC grew its holdings in shares of Delcath Systems by 81.2% during the third quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock worth $2,779,000 after purchasing an additional 307,453 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Price Performance

Delcath Systems stock opened at $7.07 on Wednesday. The business has a 50 day simple moving average of $4.89 and a 200 day simple moving average of $4.15. The company has a market capitalization of $196.40 million, a PE ratio of -2.38 and a beta of 0.55. Delcath Systems has a one year low of $2.25 and a one year high of $7.99.

Delcath Systems (NASDAQ:DCTHGet Free Report) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative return on equity of 563.60% and a negative net margin of 2,308.86%. The company had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.48 million. During the same period last year, the business earned ($0.86) earnings per share. Equities analysts anticipate that Delcath Systems will post -1.45 earnings per share for the current fiscal year.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read More

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.